By PPN Staff
The FDA approved pozelimab-bbfg (Veopoz, Regeneron) as the first treatment for CD55-deficient protein-losing enteropathy, also known as complement hyperactivation, angiopathic thrombosis and protein-losing enteropathy, or CHAPLE disease. The complement inhibitor was granted approval for adult and pediatric patients aged 1 year and older.
Fewer than 100 patients have been diagnosed with CHAPLE disease worldwide, according to the FDA. This extremely rare disease, which stems from
AUGUST 21, 2023